Aimed Bio said on the 3rd that it signed a joint research agreement with AVIS, a corporations developing AI-based digital pathology and biomarker (biological indicator) quantitative analysis solutions, to use AI technology for biomarker quantification and completed a strategic equity investment.
This is a decision to strengthen competitiveness in developing Antibody-Drug Conjugate (ADC) drugs. AVIS is a corporations that develops a platform that analyzes digital pathology images with AI to quantify biomarker expression and support clinical decision-making. Aimed Bio plans to use AVIS's Qanti Discovery to advance pathology data generated during ADC development with AI-based quantitative analysis technology and to raise the likelihood of clinical success with a biomarker-centered patient selection strategy.
AVIS's flagship product, Qanti IHC, is an AI medical device that precisely analyzes immunohistochemistry (IHC) stained slides at the cellular level. In Sep. 2024, it received Ministery of Food and Drug Safety (MFDS) approval as an in vitro diagnostic medical device and is now in use at more than 10 general hospitals in Korea, helping pathologists improve diagnostic accuracy. It is expanding the clinical application of biomarker analysis technology through licensing and collaboration with global corporations such as Philips and AstraZeneca.
Aimed Bio said it plans to push forward in stages through this joint research to automate analysis of nonclinical and clinical pathology data, improve precision in patient selection, and establish an AI-based companion diagnostics (CDx) strategy. A company official said, "In the ADC era, AI-based digital pathology and biomarker quantitative analysis capabilities are key differentiators," adding, "Through this collaboration, we will strengthen a data-driven drug development framework and enhance competitiveness in clinical development."